Experienced in Neurotoxicity Syndromes

Dr. Antonio M. Omuro

Neurology
300 Pasteur Dr, 
Stanford, CA 
Offers Telehealth
24 Years of Experience
Experienced in Neurotoxicity Syndromes
300 Pasteur Dr, 
Stanford, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Antonio Omuro is a Neurologist in Stanford, California. Dr. Omuro has been practicing medicine for over 24 years and is rated as an Experienced provider by MediFind in the treatment of Neurotoxicity Syndromes. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Gliomatosis Cerebri.

His clinical research consists of co-authoring 120 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Neurotoxicity Syndromes.

Specialties
Neurology
Licenses
Psychiatry & Neurology in FL
Hospital Affiliations
Stanford Health Care
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

STANFORD HEALTH CARE
300 Pasteur Dr, Stanford, CA 94305

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Suspended
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
A Multi-Center Phase 0/I Trial of Anti-TIGIT Antibody AB154 in Combination With Anti-PD-1 Antibody AB122 for Recurrent Glioblastoma.
A Multi-Center Phase 0/I Trial of Anti-TIGIT Antibody AB154 in Combination With Anti-PD-1 Antibody AB122 for Recurrent Glioblastoma.
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug
Study Drugs: AB122, AB154
Study Phase: Early Phase 1
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: INO-5401, INO-9012, Cemiplimab, Temozolomide
Study Phase: Phase 1/Phase 2
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug
Study Drugs: Carboxyamidotriazole orotate, Temodar®
Study Phase: Phase 1
A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Drug
Study Phase: Not Applicable
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2025
Intervention Type: Other, Drug
Study Drugs: Vemurafenib, Cobimetinib
Study Phase: Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2024
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma (PCNSL)
Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma (PCNSL)
Enrollment Status: Completed
Publish Date: April 01, 2024
Intervention Type: Other
Study Drugs: Rituximab, Methotrexate, Vincristine, Procarbazine, Busulfan, Thiotepa, Cyclophosphamide
Study Phase: Phase 2
A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma
A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma
Enrollment Status: Completed
Publish Date: October 27, 2023
Intervention Type: Drug
Study Drug: Temozolomide Followed by High Dose Busulfan and Thiotepa
Study Phase: Phase 2
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
Enrollment Status: Completed
Publish Date: October 06, 2023
Intervention Type: Biological, Other
Study Drugs: Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Anti-CD137
Study Phase: Phase 1
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide
Enrollment Status: Terminated
Publish Date: October 06, 2023
Intervention Type: Biological, Other
Study Drug: NT-I7
Study Phase: Phase 1
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
A PHASE I DOSE ESCALATION STUDY OF HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY WITH BEVACIZUMAB IN THE TREATMENT OF RECURRENT MALIGNANT GLIOMA
A PHASE I DOSE ESCALATION STUDY OF HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY WITH BEVACIZUMAB IN THE TREATMENT OF RECURRENT MALIGNANT GLIOMA
Enrollment Status: Completed
Publish Date: November 22, 2019
Intervention Type: Other
Study Phase: Phase 1
View 12 Less Clinical Trials

120 Total Publications

Phase I/II and Window-of-Opportunity Study of Pamiparib and Metronomic Temozolomide for Recurrent IDH Mutant Gliomas.
Phase I/II and Window-of-Opportunity Study of Pamiparib and Metronomic Temozolomide for Recurrent IDH Mutant Gliomas.
Journal: Neuro-oncology
Published: July 14, 2025
Similar Doctors
Distinguished in Neurotoxicity Syndromes
Dr. Brian J. Scott
Neurology
Distinguished in Neurotoxicity Syndromes
Dr. Brian J. Scott
Neurology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances

Brian Scott is a Neurologist in Stanford, California. Dr. Scott is rated as a Distinguished provider by MediFind in the treatment of Neurotoxicity Syndromes. His top areas of expertise are Neurotoxicity Syndromes, Miller-Fisher Syndrome, Chronic Polyradiculoneuritis, and Guillain-Barre Syndrome.

Advanced in Neurotoxicity Syndromes
Dr. Edgardo G. Alicaway
Neurology
Advanced in Neurotoxicity Syndromes
Dr. Edgardo G. Alicaway
Neurology
1800 Sullivan Ave, Suite 508, 
Daly City, CA 
 (23.7 miles away)
650-756-2597
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Edgardo Alicaway is a Neurologist in Daly City, California. Dr. Alicaway is rated as an Advanced provider by MediFind in the treatment of Neurotoxicity Syndromes. His top areas of expertise are Unverricht-Lundborg Syndrome, Lafora Disease, Progressive Myoclonic Epilepsy, and Dravet Syndrome.

Advanced in Neurotoxicity Syndromes
Dr. Carl A. Gold
Neurology
Advanced in Neurotoxicity Syndromes
Dr. Carl A. Gold
Neurology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances

Carl Gold is a Neurologist in Stanford, California. Dr. Gold is rated as an Advanced provider by MediFind in the treatment of Neurotoxicity Syndromes. His top areas of expertise are Encephalitis, Meningitis, Guillain-Barre Syndrome, and Seizures.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Omuro's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile